Bayer has signed a deal to help Germany-based CureVac get its coronavirus vaccine across the finish line. Under the agreement, the Big Pharma company will provide expertise in development, regulatory affairs, clinical trials, infrastructure and supply chain management.
So far, the match-up does not involve a manufacturing agreement — but that could change down the road.
CureVac launched a late-stage trial of its mRNA candidate in Europe and Latin America last month.
Although other mRNA vaccines from Pfizer and Moderna are already being rolled out, CureVac says that its candidate will not have the same storage and shipping challenges as its rivals. The companies anticipate that their candidate will become part of a second wave of approved vaccines and that it will make a meaningful impact on the efforts to end the pandemic.
Read the Bloomberg report.
